Novo Nordisk's Investor Day Fails to Excite Market
At its investor day in London, Novo Nordisk outlined a strategy for sustaining growth after patent expirations on its blockbuster obesity drugs like Wegovy and Ozempic. However, the event left analysts underwhelmed due to lack of new or compelling data, thin guidance, and no major acquisition announcements despite expectations. Deutsche Bank downgraded its target price from DKK265 to DKK245 while maintaining a
Tickers: $NVO
Topics: GLP-1 drugs market response Novo Nordisk Ozempic patent expiration strategy Wegovy